Management of lysosomal disorders has been suffering the impact of the COVID-19 pandemic. Here, an analysis of the SARS-CoV-2 pandemic impact in the Spanish Gaucher Disease (GD) community is presented. The study of the impact was performed trough paired phone interviews in which the personal health condition, therapy, contact with covid19 infected person and impact of day-a-day life was assessed. 120 GD patients, all of them included in the Spanish Registry of GD, were contacted during two rounds; first in April and second during September 2020. A total of 115 patients or relatives accepted to participated and their surveys were analyzed. The median age was 47 y.o., 31 patients were ≥ 60 y.o.; and 34% of patients reported comorbidities. 46% (50/115) of patients were treated by enzyme replacement therapy (ERT), 48 of them at hospitals; 45.1% (55/115) were on substrate reduction therapy (SRT) and 9% (10/115) receive no therapy. 25% (11/50) of ERT-hospital-based patients reported therapy interruptions, while SRT-patients did not report missing doses. Face-to-face visits have been interrupted, nevertheless no bone crises were reported. 50% (55/115) of patients reported being worried about their predisposition to a severe SARS-COV-2 infection, of them 29% (16/55) took anxiolytics or antidepressants for this. On first-round, two confirmed SARS-CoV-2 infections were reported in splenectomyzed patients, one of them (a 79-year-old diabetic) died, however no patients reported to be a contact of a person with a COVID-19 confirmed infection. During second round, 10 patients reported to had contact with an infected person, five patients were switched to oral therapy.
Conclusions: one quarter of the patients treated at hospitals reported dose interruptions and 10% of ERT cases were switched to SRT motivated for the pandemic, clinical controls suffer delays, among other changes. A substudy about antibody tests will be presented at the symposium in case of acceptance.